Healthcare

CurveBeam said it secured five purchase orders for HiRise systems during Q1 FY27, which it described as the highest first-quarter sales result to date. Customer receipts were A$1.80 million, down from A$2.58 million in Q4 FY26.

Epiminder announced on 5 November 2026 that the Centers for Medicare and Medicaid Services had finalised the CY2027 Hospital Outpatient Prospective Payment System rule, assigning the Minder System implant procedure to Ambulatory Payment Classification 5117. The national Medicare payment rate is US$31,265, compared with …

On 6 November 2026, Mayne Pharma announced that it had entered into a binding share sale agreement with an entity owned by General Pharma Bidco Pty Ltd, the vehicle for Evaris Pharma, for the sale of Mayne Pharma International Pty Ltd. Cash consideration is …

Nyrada reported that four hospitals had been activated and were screening patients in the PROTECT-MI Phase IIa clinical trial, with three patients dosed. A further four sites are expected to be activated by the end of November 2026, and recruitment is expected to accelerate …

On 6 November 2026, Pacific Edge noted that the final Local Coverage Determination for urine-based biomarkers in patients with microhematuria had been published to the Medicare Coverage Database. The determination confirms Medicare coverage for Cxbladder Triage and Triage Plus. The final determination is scheduled …

The company said LDAi had been selected for COPD detection across a major US Veterans Affairs healthcare network, under a five-year agreement with an initial one-year term and annual extensions. A bipartisan bill introduced in the US House would direct the VA to set …

Total revenue from ordinary activities was A$735.8 million, down A$5.5 million or 0.7% on FY25. Underlying EBITDA was A$204.5 million, up 0.2%, and underlying NPAT was A$35.5 million, up 4.3%. The company's full annual financial report and investor presentation accompanied the results.